ORBIMED ADVISORS LLC 13D and 13G filings for Arcutis Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-08-26 4:12 pm Sale |
2022-08-24 | 13D | Arcutis Biotherapeutics, Inc. ARQT |
ORBIMED ADVISORS LLC | 2,828,356 4.700% |
-318,368 (-10.12%) |
Filing |
| 2022-08-08 4:26 pm Sale |
2022-08-04 | 13D | Arcutis Biotherapeutics, Inc. ARQT |
ORBIMED ADVISORS LLC | 3,146,724 5.400% |
-387,813 (-10.97%) |
Filing |
| 2022-06-28 4:22 pm Sale |
2022-06-24 | 13D | Arcutis Biotherapeutics, Inc. ARQT |
ORBIMED ADVISORS LLC | 3,534,537 6.900% |
-306,027 (-7.97%) |
Filing |
| 2022-04-08 5:20 pm Sale |
2022-04-06 | 13D | Arcutis Biotherapeutics, Inc. ARQT |
ORBIMED ADVISORS LLC | 3,840,564 7.600% |
-427,000 (-10.01%) |
Filing |
| 2021-02-08 9:54 pm Unchanged |
2021-02-05 | 13D | Arcutis Biotherapeutics, Inc. ARQT |
ORBIMED ADVISORS LLC | 4,267,564 8.800% |
0 (Unchanged) |
Filing |
| 2020-10-07 5:08 pm Purchase |
2020-10-02 | 13D | Arcutis Biotherapeutics, Inc. ARQT |
ORBIMED ADVISORS LLC | 4,267,564 9.900% |
200,000 (+4.92%) |
Filing |